King Pharmaceuticals, Inc. - Sterile Products Operations Offers New Dosage Strengths of AVINZA(R) to Provide More Treatment Options for People with Chronic Pain

BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE: KG) today announced the launch of two new FDA-approved dosage strengths for AVINZA® (morphine sulfate extended-release capsules). The new dosing strengths, 45mg and 75mg, complement the currently available 30mg, 60mg, 90mg and 120mg dosages. AVINZA® is a long-acting opioid for patients with moderate to severe chronic pain who require around-the-clock pain relief for an extended period of time.